Search Results for "Gastroenterology"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Gastroenterology. Results 41 to 50 of 85 total matches.

Alpha1-Proteinase Inhibitor for Alpha1-Antitrypsin Deficiency

   
The Medical Letter on Drugs and Therapeutics • Mar 11, 1988  (Issue 761)
J Med, 314:736, 1986; JJ Crowley et al, Gastroenterology, 93:242, 1987). Homozygotes (about 2 ...
Human alpha1-proteinase inhibitor (Prolastin Cutter), possibly better known as alpha1-antitypsin (ATT), is now available in the USA for replacement therapy in patients with emphysema who have a congential deficiency of the protein.
Med Lett Drugs Ther. 1988 Mar 11;30(761):29-30 |  Show IntroductionHide Introduction

Misoprostol

   
The Medical Letter on Drugs and Therapeutics • Mar 10, 1989  (Issue 787)
associated with NSAIDs are uncommon (DY Graham, Gastroenterology, 96:675, Feb 1989). MECHANISM OF ACTION ...
Misoprostol (Cytotec - Searle), a synthetic methyl analog of prostaglandin E1, was recently approved by the US Food and Drug Administration for prevention of gastric ulcers in high-risk patients taking nonsteroidal anti-inflammatory drugs (NSAIDs). In other countries, the drug is also marketed for treatment of idiopathic peptic ulcers unrelated to NSAIDs.
Med Lett Drugs Ther. 1989 Mar 10;31(787):21-2 |  Show IntroductionHide Introduction

Drugs for GERD and Peptic Ulcer Disease

   
The Medical Letter on Drugs and Therapeutics • Apr 04, 2022  (Issue 1647)
Vaezi et al. Complications of proton pump inhibitor therapy. Gastroenterology 2017; 153:35. 11. D ...
Gastroesophageal reflux disease (GERD) is the most common GI condition encountered in the outpatient setting; it affects about 20% of people in the US.
Med Lett Drugs Ther. 2022 Apr 4;64(1647):49-56 |  Show IntroductionHide Introduction

Treatment of Clostridium Difficile Diarrhea

   
The Medical Letter on Drugs and Therapeutics • Oct 20, 1989  (Issue 803)
from the intestine (JG Bartlett et al, Gastroenterology, 89:1192, 1985). CONCLUSION — C. difficile diarrhea often ...
The gram-positive bacillus Clostridium difficile is the most common identifiable cause of antibiotic-associated diarrhea and pseudomembranous colitis (R Fekety in GL Mandell et al, eds, Principles and Practice of Infectious Diseases, 3rd ed, New York:Churchill Livingstone, 1990, page 863). C. difficile colitis usually develops during or soon after antibiotic treatment. Virtually any antimicrobial agent can cause the disorder, but clindamycin, ampicillin and the cephalosporins have been implicated most frequently. Pseudomembranous colitis was recently reported in five patients who had ...
Med Lett Drugs Ther. 1989 Oct 20;31(803):94-5 |  Show IntroductionHide Introduction

Ethanolamine Oleate For Esophageal Varices

   
The Medical Letter on Drugs and Therapeutics • Nov 03, 1989  (Issue 804)
in controlling esophageal hemorrhage and prolonging life (C Infante-Rivard et al, Gastroenterology, 96:1087, 1989 ...
Endoscopic injection of sclerosing agents is now widely accepted as a primary treatment for bleeding esophageal varices (J Terblanche et al, N Engl J Med, 320:1393, 1469, May 25 and June 1, 1989). Ethanolamine oleate 5% (Ethamolin - Glaxo), a sclerosing agent that has been available in Canada and abroad for many years, was recently approved for this indication by the US Food and Drug Administration (FDA).
Med Lett Drugs Ther. 1989 Nov 3;31(804):99-100 |  Show IntroductionHide Introduction

Oral Mesalamine for Ulcerative Colitis

   
The Medical Letter on Drugs and Therapeutics • Aug 21, 1992  (Issue 877)
; SA Riley et al, Gastroenterology, 94:1383, 1988). In one randomized, observer-blind The Medical ...
An oral formulation of mesalamine (5-aminosalicylic acid, 5-ASA, Asacol - Proctor & Gamble), was recently approved by the US Food and Drug Administration (FDA) for treatment of mildly to moderately active ulcerative colitis; it has not been approved for maintenance of remissions. Olsalazine (Dipentum), a similar drug (Medical Letter, 32:105, 1990), is approved for maintenance of remissions but not for treatment.
Med Lett Drugs Ther. 1992 Aug 21;34(877):80-1 |  Show IntroductionHide Introduction

Adderall and Other Drugs for Attention-Deficit/Hyperactivity Disorder

   
The Medical Letter on Drugs and Therapeutics • Nov 25, 1994  (Issue 936)
once daily, but rarely can cause serious hepatic toxicity (A Nehra et al, Gastroenterology, 99:1517 ...
A drug that combines the neutral sulfate salts of dextroamphetamine and racemic amphetamine with the dextro isomer of amphetamine saccharate and d,l amphetamine aspartate (Adderall - Richwood Pharmaceutical) has recently been promoted for treatment of children with Attention-Deficit/Hyperactivity Disorder (ADHD). This same mixture of amphetamine salts was previously marketed as Obetrol for treatment of obesity.
Med Lett Drugs Ther. 1994 Nov 25;36(936):109-10 |  Show IntroductionHide Introduction

Acetaminophen, Nsaids and Alcohol

   
The Medical Letter on Drugs and Therapeutics • Jun 21, 1996  (Issue 977)
who take NSAIDs (D Henry et al, Gastroenterology, 105:1078, 1993). CONCLUSION — Alcohol may increase ...
An advertising war between manufacturers of over-the-counter (OTC) analgesics has led some patients to ask their physicians about the safety of taking these products if they also drink alcohol.
Med Lett Drugs Ther. 1996 Jun 21;38(977):55-6 |  Show IntroductionHide Introduction

Primary Prevention of Ulcers in Patients Taking Aspirin or NSAIDs

   
The Medical Letter on Drugs and Therapeutics • Mar 08, 2010  (Issue 1333)
at increased risk of ulcer development: a randomized controlled trial (OBERON). Gastroenterology 2009; 136 ...
Aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) are common causes of peptic ulcer disease. Patients infected with Helicobacter pylori who take aspirin or another NSAID have an especially high risk. Drugs that have been tried for prevention of ulcers in patients taking NSAIDs including H2-receptor antagonists, proton pump inhibitors (PPIs), aluminum- or magnesium-containing antacids, the prostaglandin misoprostol (Cytotec, and others), and antibiotics to eradicate H. pylori.Click here to view the free full...
Med Lett Drugs Ther. 2010 Mar 8;52(1333):17-9 |  Show IntroductionHide Introduction

Drugs for Helicobacter pylori Infection

   
The Medical Letter on Drugs and Therapeutics • Jul 17, 2017  (Issue 1525)
: a systematic review and metaanalysis. Gastroenterology 2016; 150:1113. 4. CA Fallone et al. The Toronto ...
About 50% of the world’s population is infected with Helicobacter pylori. These gastric bacteria can cause chronic inflammation and have been associated with development of gastritis, peptic ulcer disease, gastric adenocarcinoma, and gastric mucosa-associated lymphoid tissue (MALT) lymphoma. Eradication of H. pylori can promote gastric healing, prevent recurrence of duodenal and gastric ulcers, and reduce the incidence of gastric cancer. Guidelines for treatment of H. pylori infection were updated recently.
Med Lett Drugs Ther. 2017 Jul 17;59(1525):113-7 |  Show IntroductionHide Introduction